KADCYLA 160 MG PD. VIAL FOR INF

Indication Used in HER2-positive metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects such as hepatotoxicity embryo-fetal toxicity and cardiac toxicity.